AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3161487 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 48
Study 30501605 — intervention group
Group type: EXPERIMENTAL
Intervention: BPF (standard bergamot polyphenolic fraction)
Number of subjects: 60
Study 30501605 — intervention group
Group type: EXPERIMENTAL
Intervention: BPF Phyto (phytosomal formulation of bergamot polyphenolic fraction)
Number of subjects: 60
Study 30501605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Swipe with gloved finger
Number of subjects: 12
Study 28466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Swipe with cloth
Number of subjects: 12
Study 28466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Wipe from wet bloodstains
Number of subjects: 12
Study 28466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall classification of pattern types
Number of subjects: 12
Study 25924202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 0
Study 25924202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22935006 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and tea catechin supplementation
Number of subjects: 128
Study 22935006 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 128
Study 22935006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea catechin supplementation
Number of subjects: 128
Study 22935006 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 128
Study 20383510 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (2.5 mg in 20 ml saline)
Number of subjects: 75
Study 20383510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml saline)
Number of subjects: 75
Study 20383510 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (5 mg in 20 ml saline)
Number of subjects: 75
Study 18619622 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT)
Number of subjects: 72
Study 18619622 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 72
Study 17432639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Dazhui (GV 14)
Number of subjects: 261
Study 17432639 — intervention group
Group type: COMPARATOR
Intervention: Antondine injection (Control)
Number of subjects: 261
Study 12799126 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + nurse case manager (NCM)
Number of subjects: 186
Study 12799126 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + community health worker (CHW)
Number of subjects: 186
Study 12799126 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + nurse case manager/community health worker team
Number of subjects: 186
Study 12799126 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 186
Study 10641772 — intervention group
Group type: EXPERIMENTAL
Intervention: APD treatment
Number of subjects: 34
Study 10641772 — intervention group
Group type: COMPARATOR
Intervention: CAPD treatment
Number of subjects: 34
Study 9032854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery with a mean dose of 12.1 Gy
Number of subjects: 29
Study 1647919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous total parenteral nutrition (infused continuously over 24 h)
Number of subjects: 12
Study 1647919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (infused between 22.00 and 10.00 hours)
Number of subjects: 12
Study 1647919 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Continuous and Cyclic total parenteral nutrition)
Number of subjects: 12
Study 6347581 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily
Number of subjects: 99
Study 6347581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 3910159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay open treatment (n = 26)
Number of subjects: 47
Study 3910159 — intervention group
Group type: COMPARATOR
Intervention: Excision treatment (n = 21)
Number of subjects: 47
Study 30170422 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth exercise training program (8-week duration, 32 sessions)
Number of subjects: 98
Study 30170422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 98
Study 27627782 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride, 50 mg/d
Number of subjects: 80
Study 27627782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24967363 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological Cost Index (PCI) during walking over ground and on the Gait Trainer (GT) with body weight support (BWS)
Number of subjects: 12
Study 22818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 628
Study 22818074 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 628
Study 22818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) via transapical approach
Number of subjects: 628
Study 22818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) via transfemoral approach
Number of subjects: 628
Study 20502223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plavix (PG)
Number of subjects: 61
Study 20502223 — intervention group
Group type: COMPARATOR
Intervention: Control (NPG)
Number of subjects: 61
Study 17640035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-weighted Cox model
Number of subjects: 0
Study 17640035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-weighted Weibull model
Number of subjects: 0
Study 15762190 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment (50 mg/day for 9 days)
Number of subjects: 9
Study 15762190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 14696887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.35 mg x kg(‐1)
Number of subjects: 50
Study 14696887 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg x kg(‐1)
Number of subjects: 50
Study 14696887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 50
Study 14696887 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study 14696887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ketorolac and Morphine
Number of subjects: 50
Study 10826388 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-interaction model
Number of subjects: 0
Study 8979201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (39 patients, 51%)
Number of subjects: 75
Study 8979201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (36 patients, 49%)
Number of subjects: 75
Study 1476266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral defibrotide in association with diet and oral antidiabetic drugs
Number of subjects: 117
Study 1476266 — intervention group
Group type: COMPARATOR
Intervention: Diet and antidiabetic agents (Control)
Number of subjects: 117
Study 1476266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral defibrotide
Number of subjects: 117
Study 6435481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (iv NTG) infusion at 0.5 microgram . kg‐1 . min‐1 for 20 min prior to induction of anesthesia and throughout the study
Number of subjects: 20
Study 6435481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31060839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 65
Study 29421218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically delivered kynurenic acid cream
Number of subjects: 0
Study 29421218 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 27863615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essence inhalation (2 drops at 4-5, 6-7, 8-9 cm cervical dilation)
Number of subjects: 120
Study 27863615 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 120
Study 24672938 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (treatment group)
Number of subjects: 55
Study 24672938 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART combined with Qiling Decoction (combination group)
Number of subjects: 55
Study 24672938 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 55
Study 23154391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site access (LESS)
Number of subjects: 200
Study 23154391 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-port laparoscopic appendectomy (TPLA)
Number of subjects: 200
Study 19850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PKAN
Number of subjects: 17
Study 19850762 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 19029207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach to sample size calculations from an industry perspective
Number of subjects: 0
Study 19029207 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected value of information methods
Number of subjects: 0
Study 15764627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 15764627 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study 12495231 — intervention group
Group type: EXPERIMENTAL
Intervention: Origami exercises
Number of subjects: 12
Study 12495231 — intervention group
Group type: COMPARATOR
Intervention: Size comparison tasks only (Control)
Number of subjects: 12
Study 10478805 — intervention group
Group type: EXPERIMENTAL
Intervention: Training rehabilitation (group Tr, n=20)
Number of subjects: 40
Study 10478805 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (group C, n=20)
Number of subjects: 40
Study 8648209 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (600 mg, 3 times/day) alone or in combination with zidovudine (200 mg, 3 times/day)
Number of subjects: 0
Study 8648209 — intervention group
Group type: COMPARATOR
Intervention: Combination of saquinavir, zidovudine, and dideoxycytidine
Number of subjects: 0
Study 8648209 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic analysis of saquinavir resistance
Number of subjects: 0
Study 8648209 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of genotypic resistance
Number of subjects: 0
Study 8648209 — intervention group
Group type: EXPERIMENTAL
Intervention: Met90 mutation
Number of subjects: 0
Study 1924611 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative counselor condition
Number of subjects: 75
Study 1924611 — intervention group
Group type: COMPARATOR
Intervention: Nonfacilitative counselor condition
Number of subjects: 75
Study 7042029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole (n = 46)
Number of subjects: 97
Study 7042029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metronidazole (n = 51)
Number of subjects: 97
Study 31916890 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 15
Study 31157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid (Ringerfundin)
Number of subjects: 30
Study 31157652 — intervention group
Group type: COMPARATOR
Intervention: Colloid (6% hydroxyethyl starch, HES)
Number of subjects: 30
Study 31157652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 27593842 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization on days 2-5 post-bleeding
Number of subjects: 65
Study 27593842 — intervention group
Group type: COMPARATOR
Intervention: Verticalization on day 12 post-bleeding
Number of subjects: 65
Study 25684005 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1.0 ng/mL (group R1.0)
Number of subjects: 128
Study 25684005 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1.5 ng/mL (group R1.5)
Number of subjects: 128
Study 25684005 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil effect-site concentration of 0 ng/mL (group R0)
Number of subjects: 128
Study 25684005 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 0.5 ng/mL (group R0.5)
Number of subjects: 128
Study 23672916 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 78
Study 23672916 — intervention group
Group type: COMPARATOR
Intervention: Manual TKA
Number of subjects: 78
Study 23672916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiographs (mechanical axis)
Number of subjects: 78
Study 21836540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with tacrolimus monotherapy
Number of subjects: 123
Study 21836540 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab induction with tacrolimus/mycophenolate combination
Number of subjects: 123
Study 21836540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 123
Study 19792844 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus PDT
Number of subjects: 45
Study 19792844 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus systemic doxycycline
Number of subjects: 45
Study 19792844 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP only
Number of subjects: 45
Study 16772244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (240 mL, 12 g of lactose)
Number of subjects: 49
Study 16772244 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free milk
Number of subjects: 49
Study 15471317 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS)
Number of subjects: 0
Study 11370406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0
Study 11370406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, ketoconazole, and itraconazole
Number of subjects: 0
Study 9269944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of benazepril (10 mg) and low-dose amlodipine (2.5 mg)
Number of subjects: 24
Study 9269944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8304707 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MePr)
Number of subjects: 57
Study 8304707 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone methylsulfobenzoate (MsPr)
Number of subjects: 57
Study 8304707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 57
Study 3661923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl
Number of subjects: 24
Study 3661923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl
Number of subjects: 24
Study 3661923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 24
Study 29498753 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based alcohol intervention (TM)
Number of subjects: 15
Study 29498753 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 15
Study 27265743 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 27265743 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 0
Study 27265743 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC; erlotinib, gemcitabine, or vinorelbine)
Number of subjects: 0
Study 27265743 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab or Tremelimumab as monotherapy
Number of subjects: 0
Study 25953222 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.66 mg/L)
Number of subjects: 120
Study 25953222 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.33 mg/L)
Number of subjects: 120
Study 23963340 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG triggered electrical stimulation (EMG‐ES) plus unilateral task practice
Number of subjects: 21
Study 23963340 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG triggered electrical stimulation (EMG‐ES) plus bilateral task practice
Number of subjects: 21
Study 23963340 — intervention group
Group type: COMPARATOR
Intervention: EMG triggered electrical stimulation (EMG‐ES)
Number of subjects: 21
Study 22338128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic surface positioning group
Number of subjects: 150
Study 22338128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided group
Number of subjects: 150
Study 22338128 — intervention group
Group type: COMPARATOR
Intervention: Anatomic landmark group
Number of subjects: 150
Study 19478257 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg, twice daily) added to metronidazole
Number of subjects: 50
Study 19478257 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 50
Study 17725894 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 0
Study 15573850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 doses of 6 mg IV)
Number of subjects: 30
Study 15573850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11300573 — intervention group
Group type: EXPERIMENTAL
Intervention: Schematic threatening faces
Number of subjects: 0
Study 11300573 — intervention group
Group type: COMPARATOR
Intervention: Schematic friendly faces
Number of subjects: 0
Study 11300573 — intervention group
Group type: COMPARATOR
Intervention: Schematic neutral faces
Number of subjects: 0
Study 11300573 — intervention group
Group type: EXPERIMENTAL
Intervention: Schematic angry faces
Number of subjects: 0
Study 11300573 — intervention group
Group type: COMPARATOR
Intervention: Schematic sad or scheming faces
Number of subjects: 0
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level >100,000 copies/mL
Number of subjects: 254
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4 cell percent <15%
Number of subjects: 254
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased HIV-1 RNA levels after baseline
Number of subjects: 254
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell percent dropped to <15%
Number of subjects: 254
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: Log10 increase in HIV-1 RNA copy numbers
Number of subjects: 254
Study 9129063 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percentage point decrement in CD4 cell percent
Number of subjects: 254
Study 7880700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium pretreatment
Number of subjects: 100
Study 7880700 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium alone
Number of subjects: 100
Study 7880700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 100
Study 2646536 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 230
Study 2646536 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 230
Study 2646536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 2646536 — intervention group
Group type: COMPARATOR
Intervention: Control (No Milrinone)
Number of subjects: 230
Study 33454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole in 54 patients
Number of subjects: 104
Study 33454 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients)
Number of subjects: 104
Study 33454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 104
Study 33454 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 31893603 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-proseal (LMAP)
Number of subjects: 90
Study 31893603 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-classic (LMAC)
Number of subjects: 90
Study 31893603 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-flexible (LMAF)
Number of subjects: 90
Study 28521773 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice
Number of subjects: 60
Study 28521773 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 60
Study 25264190 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Constellation Seminars (FCSs) - 3-day intervention
Number of subjects: 104
Study 26231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with focus on lifestyle (n = 90)
Number of subjects: 180
Study 26231850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session, 1.5 h/week group treatment with focus on parenting (n = 45)
Number of subjects: 180
Study 26231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Same group treatment as 2) with additional follow-up sessions (n = 45)
Number of subjects: 180
Study 23601801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FA) implants
Number of subjects: 0
Study 23601801 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 0
Study 21088650 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 1425
Study 21088650 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 1425
Study 21088650 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 1425
Study 17945409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg
Number of subjects: 253
Study 17945409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 16600931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 39
Study 14710100 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg vaginally administered isosorbide mononitrate
Number of subjects: 0
Study 14710100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0